Skip to content

The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke

The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03093142
Enrollment
45
Registered
2017-03-28
Start date
2017-03-01
Completion date
2020-12-30
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Cognitive Impairment

Keywords

transcranial direct current stimulation (tDCs), neurofeedback

Brief summary

This is a double blinded, randomized control trial with a pretest-posttest control and interventional groups design. Both the assessor and participants are blinded to all assessments and evaluations. All patients with subacute stroke undergo in-patient or out-patient rehabilitation are screened initially by a series of screening test. Suitable patients are assigned randomly to 3 groups respectively. Group 1 is the combined transcranial direct current stimulation (tDCS) and neurofeedback group. Group 2 is the neurofeedback group. Group 3 is the control group with sham neurofeedback training.

Detailed description

Treatment sessions for all three groups are conducted by the investigators who has training in neurofeedback and transcranial direct current stimulation (tDCs). Each participant performed 10 training sessions on different days. Sessions were conducted 3-5 times a week The tDCS + neurofeedback group will carry out 30 minutes tDCS and 30 minutes neurofeedback training. The real neurofeedback group will carry out 30 minutes neurofeedback training. The sham neurofeedback group will conduct the 30 minutes sham neurofeedback training.

Interventions

DEVICEtDCS & neurofeedback

tDCs and neurofeedback

DEVICEneurofeedback

Neurofeedback

sham neurofeedback

Sponsors

Chinese University of Hong Kong
CollaboratorOTHER
Kowloon Hospital, Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. First or second stroke (haemorrhagic or ischaemic) confirmed by computer axial tomography scan or magnetic resonance imaging 2. Below 16 th percentile cut off in Hong Kong Montreal - Cognitive Assessment (HK - MoCA) (range from 17-25/30). 3. Less than twelve months since onset of stroke at study entry 4. Able to follow simple command

Exclusion criteria

1. Patients with severe dysphasia (either expressive or comprehensive) which restricts communication; 2. History of other neurological disease, psychiatric disorder, or alcoholism; 3. Significant impairment in visual or auditory function 4. Any additional medical or psychological condition that would affect their ability to comply with the study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Change score in Trail Making Test A & B from baselineOne day before the treatment , up to 4 weeks, up to 16 weeksTrail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.

Secondary

MeasureTime frameDescription
Change score in Functional Independence Measure (FIM) from baselineOne day before the treatment , up to 4 weeks, up to 16 weeksThe Functional Independence Measure instrument is a basic indicator of patient disability. FIM is used to track the changes in the functional ability of a patient during an episode of hospital rehabilitation care.
Change score in Stroke Adapted 30 item version of the Sickness Impact Profile (SA - SIP 30)One day before the treatment , up to 4 weeks, up to 16 weeksSA-SIP 30 assesses quality of life in patients who have sustained a stroke.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026